Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	249.99	+0.00 (0.00%)
AAPL	326.59	+0.00 (0.00%)
AMD	503.57	+0.00 (0.00%)
BAC	60.42	+0.00 (0.00%)
GOOG	351.37	+0.00 (0.00%)
META	645.85	+0.00 (0.00%)
MSFT	402.29	+0.00 (0.00%)
NVDA	203.28	+0.00 (0.00%)
ORCL	121.38	+0.00 (0.00%)
TSLA	369.57	+0.00 (0.00%)

Symbol

Price

Change (%)

AMZN

249.99

+0.00 (0.00%)

AAPL

326.59

+0.00 (0.00%)

AMD

503.57

+0.00 (0.00%)

BAC

60.42

+0.00 (0.00%)

GOOG

351.37

+0.00 (0.00%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes